Home - Ryvu Therapeutics

FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual EHA Congress. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini.
Representatives of the Ministry of Economic Development, Labour and Technology visited Ryvu Therapeutics

At Ryvu, we develop therapeutics that address clinical limitations of current treatments in oncology.

Our pipeline includes candidates with differentiated properties from kinase, synthetic lethality, immuno-oncology and immunometabolism programs.

See our Pipeline

KINASE INHIBITORS

Synthetic Lethality

Immuno-Oncology

Cancer Metabolism

Ryvu Therapeutics (Selvita Oncology) was founded in 2007. Since 2014, the company has been listed on Warsaw Stock Exchange under the ticker RVU.

Ryvu Therapeutics is organized for highly efficient R&D driven by breakthrough science, aiming to realize full value potential for its shareholders, partners and employees.

55.60 PLN -2.46% RVU • 23/07/2021 17:00 • Warsaw Stock Exchange

Do you want to challenge and be challenged?

Do you want to have an impact on the world?
Please see our current openings to learn more about our work.

Join Us

Developing therapeutics
at the forefront of oncology

News Releases

What we do

We challenge current treatment paradigms

Investor Relations

Let's Grow Together